Improving heart disease risk assessment for people living with HIV
Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial
This study is working to create a better way to predict heart disease risk for people living with HIV by looking at different health factors, so that those individuals can get more personalized care and support.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11051219 on NIH RePORTER |
What this research studies
This research aims to create a more accurate cardiovascular disease (CVD) risk score specifically for individuals living with HIV. By utilizing data from the REPRIEVE trial, the study will integrate various factors such as inflammatory and immune biomarkers, imaging results, and genetic information to better understand the unique risks faced by this population. The researchers will analyze existing CVD risk prediction scores and their effectiveness in predicting heart disease in people with HIV, ultimately aiming to develop a tailored risk assessment tool that reflects the complexities of HIV-related cardiovascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are at risk for cardiovascular disease.
Not a fit: Patients who do not have HIV or those who are not at risk for cardiovascular disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart disease prevention strategies for individuals living with HIV.
How similar studies have performed: Previous research has shown that tailored risk assessment tools can improve health outcomes in specific populations, suggesting potential success for this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Triant, Virginia Athena — Massachusetts General Hospital
- Study coordinator: Triant, Virginia Athena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.